GLP-1 drug shortages, driven by cosmetic and weight loss purposes, result in access disparities among individuals with ...

New data shows that government-funded health insurance plans in the United States provide the majority of coverage for ...

With brand-name GLP-1s for obesity treatment on and off the shortage list, prescribing can get complicated. Five providers ...

Patients who would benefit from a GLP-1 face significant challenges when it comes to access. Shortages have made it difficult ...

In October, the FDA removed Mounjaro and Zepbound—the diabetes and obesity GLP-1 drugs made by Eli Lilly—from the shortage ...

U.S. government health plans account for the lion's share of coverage for popular new weight-loss drugs, far beyond the ...

Pharmacies that make customized medications are asking the federal Food and Drug Administration to protect their right to ...

Nov. 6, 2024 – The FDA has updated the labels for all GLP-1 weight loss drugs with a warning about pulmonary aspiration ...

The FDA updated GLP-1 drug labels to warn of the risk of patients breathing food into their lungs while under anesthesia for ...

Research shows that 1 in 8 adults in the US has used one of the popular GLP-1 medications, most of them trying to manage ...